Inspira Technologies Enhances AI-Powered HYLA Blood Sensor with Advanced Oxygenation Indicator
Inspira Technologies (Nasdaq: IINN), a leader in life-support innovation, has announced the integration of a next-generation oxygenation indicator into its AI-powered HYLA™ blood sensor. This enhancement is designed to enable rapid, continuous detection of oxygen-related conditions without requiring intermittent blood draws, marking a significant advancement in critical care monitoring.
The newly integrated oxygenation indicator facilitates real-time monitoring of tissue oxygenation, allowing for early detection of hypoxia and respiratory complications. This feature positions HYLA as a disruptive technology in the $2.5 billion point-of-care testing and arterial blood gas analyzer market. By continuously tracking lung function and vital blood parameters, HYLA aims to improve patient outcomes and streamline healthcare provider responses in critical care settings.
Clinical validation of the upgraded HYLA sensor is currently underway at Sheba Medical Center, recognized as one of the world’s top 10 smart hospitals by Newsweek. Inspira Technologies expects to release preliminary clinical results in the near future. The non-invasive technology leverages advanced optical sensors and machine-learning algorithms to deliver continuous, precise monitoring of blood parameters and oxygen levels. The company anticipates submitting the device for U.S. Food and Drug Administration (FDA) clearance in the second half of 2025.
“This advancement marks an important step in transforming critical care monitoring,” said Dagi Ben-Noon, CEO of Inspira. “The integration of this new oxygenation indicator into HYLA will enable healthcare providers to monitor and respond to changes in tissue oxygenation in real-time.”
The integration also strengthens HYLA’s position as a comprehensive blood monitoring solution. Combined with the FDA-cleared INSPIRA ART100 system, the technology aims to offer a complete, non-invasive approach to patient care, maintaining patient consciousness during treatment and improving overall clinical efficiency.
You might like this article: Quantum BioPharma’s unbuzzd™ Shows Promising Results in Reducing Alcohol Intoxication and Hangover Symptoms
